Publications

Poster

The Novel Serotonin Transporter Modulator SNTX-2643: Results from a Pharmacokinetic and Target Engagement Evaluation in Healthy Adults

Psych Congress 2026
These materials are provided for scientific exchange only and for presentations, reflect data as of the date presented at the meeting noted above each poster, and have not been independently peer reviewed or updated since.

SNTX-2643 is investigational. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established. These materials may contain forward-looking statements subject to the risks of drug development, are not an offer to sell or a solicitation to buy securities, and may not be reproduced or redistributed without Sensorium's written consent. © 2026 Sensorium Therapeutics, Inc. SensAI™ is a trademark of Sensorium Therapeutics, Inc.

Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class compound under investigation for the treatment of anxiety disorders—and built a robust IP estate extending into the 2040s.

‍News  

Team

‍Careers  

‍Contact  

© 2026 Sensorium Therapeutics.
All rights reserved.
‍FCOI policy
‍Privacy policy